Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021
September 21, 2021 08:30 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Monday, September 20, 2021, at 4:30 PM ET
September 13, 2021 08:00 ET
|
Brooklyn Immunotherapeutics LLC
BROOKLYN, N.Y., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and...
Brooklyn ImmunoTherapeutics to Participate in Grand Opening of Cambridge-Based mRNA Cleanroom Facility Shared with Factor Bioscience
September 09, 2021 08:30 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum
August 20, 2021 16:15 ET
|
Brooklyn Immunotherapeutics LLC
BROOKLYN, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and...
Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from August 19, 2021
August 20, 2021 08:30 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Thursday, August 19, 2021 at 4:30 PM ET
August 16, 2021 16:15 ET
|
Brooklyn Immunotherapeutics LLC
BROOKLYN, N.Y., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and...
Brooklyn ImmunoTherapeutics Announces Second Quarter 2021 Financial Results
August 16, 2021 07:00 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that gene editing/cell and...
Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor Conference on August 18, 2021
August 13, 2021 14:22 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn Immuno Reports Inducement Grants
July 23, 2021 16:30 ET
|
Brooklyn Immunotherapeutics LLC
BROOKLYN, N.Y., July 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and...
Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics
July 19, 2021 08:00 ET
|
Brooklyn Immunotherapeutics LLC
Acquisition Advances Transformation Into Platform Company Focused on Cell, Gene Editing and Cytokine Therapy Company to hold Conference Call Today, July 19, 2021, at 4:15PM ET to Discuss the...